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CASE REPORT
A case report 
of immunosuppression-related Kaposi’s sarcoma 
after autologous stem cell transplantation
Bert Heyrman* , Ann De Becker and Rik Schots
Abstract 
Background: Kaposi’s sarcoma (KS) is a tumor formed by angioproliferations driven by Human herpes virus 8 also 
known as Kaposi’s sarcoma-associated herpes virus (KSHV). It is best known as an acquired immune deficiency syn-
drome (AIDS) defining illness that may be fatal. There are only a few reports of KS after hematopoietic cell transplanta-
tion (HCT). This is the first case describing the disappearance of KS with immune recovery after autologous HCT.
Case presentation: We present the case of a 61-year-old male heterosexual patient of Moroccan origin treated for 
primary mediastinal non-Hodgkin lymphoma. Because of refractory disease he received multiple lines of chemother-
apy prior to autologous HCT. After the second course of low-dose bis-chloroethylnitrosourea, etoposide, cytarabine, 
melphalan (BEAM) the patient developed several round blue skin lesions. A biopsy was performed, showing many 
small vessels and positive immune histochemical staining for Human herpes virus 8 (HHV-8), confirming diagnosis 
of KS. Human immunodeficiency virus testing was negative and work-up showed that there were no visceral lesions. 
When KS are limited to the skin, prognosis is usually better. The extensive chemotherapy resulted in an important 
immunosuppression; on day 105 after autologous HCT CD4+ count was 82/mm3. Since KS were limited to the skin 
and attributed to severe immune suppression a watchful waiting strategy was adopted even though in the first 
months after autologous HCT new skin lesions appeared. With immune recovery (CD4+ count > 200/mm3) 277 days 
after transplant, skin lesions faded.
Conclusion: Kaposi’s sarcoma remains a rare tumor that should be thought of in any patient whose immunity is 
down. If immune recovery is expected and disease is limited to the skin, a watchful waiting strategy can be more 
rewarding than intensive chemotherapy.
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Background
Kaposi’s sarcoma (KS) is a tumor characterized by 
mucocutaneous and visceral angioproliferations, first 
described by Moritz Kaposi in 1872 [1]. Today four clini-
cal variants of KS are known [1] with similar histologic 
findings but different sites of involvement and rates of 
progression. Classic Kaposi’s sarcoma, primarily found 
in Eastern European and Mediterranean men (male to 
female ratio 15:1) is mostly limited to the skin of hands 
and feet and follows an indolent course. Endemic KS 
occurs in Africa independent of Human immunodefi-
ciency virus (HIV) infection. In children progression is 
fulminant and outcome fatal whereas in adults presen-
tation is similar to classic KS. Immunosuppression- or 
transplantation-associated KS occurs in organ-transplant 
recipients and patients receiving immunosuppressive 
therapy for other medical conditions. This type tends to 
be aggressive, involving lymph nodes, mucosa and vis-
ceral organs, sometimes in the absence of skin lesions. 
Epidemic or acquired immune deficiency syndrome 
(AIDS) associated Kaposi sarcoma is the best known 
variant and is commonly known to be an AIDS defining 
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illness in HIV patients. It is feared for its aggressive and 
frequently fatal outcome.
Only 13 cases of KS after hematopoietic cell transplan-
tation (HCT) have been described: 11 after allogeneic 
and two after autologous HCT [2–14]. The disease was 
lethal in 3/11 allogeneic and 1/2 autologous HCT. In 
adults, skin only was the dominant clinical presentation. 
All three pediatric cases had visceral involvement, result-
ing in two fatalities (after either allogeneic or autologous 
HCT). The two cases described after autologous HCT 
had visceral involvement. The adult case, while in com-
plete remission for his hematological malignancy, died 
due to disseminated KS. The pediatric case responded to 
recombinant alpha-interferon.
The driving agent for the proliferative growth is Kapo-
si’s sarcoma-associated herpes virus (KSHV) also known 
as Human herpes virus 8 (HHV-8), a group 1 carcino-
genic agent according to the International Agency for 
Research on Cancer [15]. Apart from KS, HHV-8 is the 
underlying cause of lymphoproliferative disorders such as 
primary effusion lymphoma [16] and multicentric Castle-
man disease [17]. Seroprevalence rates are low in West-
ern countries and higher in certain geographic areas (the 
Mediterranean area and Africa) [18, 19]. Human her-
pes virus 8 prevalence is high in men with homosexual 
activity, apart from HIV infection and in migrants from 
endemic regions [17]. Saliva is believed to be the major 
transmission vehicle for horizontal transmission [20, 21].
Genes encoded by KSHV can induce cellular prolif-
eration and prevent apoptosis causing a transformative 
effect on endothelial cells. In transplant recipients non-
malignant pathologic events as cytopenias and acute 
hepatitis syndromes can be provoked by KSHV [22]. One 
study however, conducted to investigate HHV-8 sero-
prevalence after allogeneic bone marrow transplantation 
(BMT) did not find any association between presence of 
antibodies directed against HHV-8 latent nuclear anti-
gen before or after transplantation, chronic graft versus 
host disease, or overall BMT survival [23]. More data are 
needed to support this finding.
In general the level of immunosuppression and the 
extent of disease determine the course of KS. Visceral KS 
is characterized by rapid spread and risk of major bleed-
ing with often fatal outcome. Skin limited KS typically 
follows an indolent course [24] and is more an aesthetic 
problem lowering self-esteem of HIV patients. In solid 
organ transplant patients 1  year survival rate is at 90  % 
for cutaneous disease and 70 % for visceral forms [25].
Immune recovery is generally defined as a rise in CD4+ 
count above 200/mm3 and was described to be associ-
ated with a gradual disappearance of KS in HIV patients 
[26, 27]. Since the introduction of HAART as a success-
ful HIV treatment resulting in less prolonged immune 
deficiency, the incidence of KS has decreased substan-
tially [28, 29].
Treatment intent and strategy differ depending on loca-
tion and spread of disease. Tapering of dose in patients 
receiving immunosuppressive medication is an option. In 
disease limited to skin only, surgical excision or electro-
chemotherapy is the most preferable approach, radio-
therapy appears to be abandoned due to local side effects 
(edema and ulcerations) [22]. In solid organ transplant 
patients intensive therapy is required in case of persistent 
functional disability or life-threatening disease [30]. Pos-
sible options are the use of interferon-alpha or chemo-
therapy using doxorubicin in monotherapy or vincristine, 
etoposide and bleomycin in monotherapy or in combina-
tion with anthracyclines [31]. The use of antiviral treat-
ment (cidofovir, foscarnet, ganciclovir or valganciclovir) 
is considered without benefit [32, 33]. Since neoplastic 
KS spindle cells harbor a latent HHV-8 infection eradi-
cation is not possible [34–36]. One could start antiviral 
therapy in cases of aggressive disseminated KS with high 
HHV-8 viremia, aiming to at least resolve cytopenias. 
Novel targeted therapies are currently under investi-
gation. Imatinib a tyrosine kinase inhibitor of c-Kit, 
expressed by KS tumor cells, showed promising results in 
a phase 2 study conducted in AIDS-related KS patients 
[37].
Here we report the rise and fall of Kaposi sarcoma of 
the skin coinciding with immunosuppression and recon-
stitution after autologous HCT in a 61-year-old patient 




A 61-year-old heterosexual male of Moroccan origin was 
diagnosed with primary mediastinal non-Hodgkin lym-
phoma. Other than hypertension treated with amlodi-
pine he had no medical history. Viral serology prior to 
starting therapy showed previous hepatitis B infection, 
HIV screening was negative.
The patient was refractory to rituximab, cyclophos-
phamide, doxorubicin, vincristine and prednisone 
(R-CHOP). Second line therapy with rituximab, dexa-
methasone, cytarabine and cisplatin (R-DHAP) had to 
be abandoned after one cycle because of invalidating tin-
nitus. Rituximab, ifosfamide, carboplatin and etoposide 
(R-ICE) was started with an increase in tumor activity 
and volume on positron emission tomography (PET)/
computed tomography (CT) after the first cycle. In 
August 2013 the patient was hospitalized for high dose 
cyclophosphamide for stem cell mobilization. Treatment 
continued with low-dose BEAM (bis-chloroethylnitro-
sourea 60 mg/m2 on day 1, etoposide 15 mg/m2 on day 
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2,3,4 and 5, cytarabine 2 × 100 mg/m2 on day 2,3,4 and 
5, and melphalan 30 mg/m2 on day 6) followed by autolo-
gous stem cell rescue, resulting in a partial response. We 
repeated low-dose BEAM followed by stem cell infu-
sion and obtained stable disease on PET/CT. After the 
second cycle we noticed blue, round lesions on the left 
forearm and both legs, slightly elevated and sensitive 
with pressure (Fig. 1). Skin biopsies were taken. Micros-
copy showed a normal epidermis, but the dermis showed 
many small vessels in clusters with swollen endothelial 
cells (Fig.  2). Immune-histochemical staining was posi-
tive for HHV-8 (Fig. 3) and negative for cytomegalovirus 
(CMV). The diagnosis of Kaposi’s sarcoma of the skin was 
made. Serology confirmed a negative HIV status. Review 
of the CT scans showed no evidence of visceral sarcomas. 
After 1  week of ganciclovir because of a positive poly-
merase chain reaction (PCR) for CMV, treatment con-
tinued with full dose BEAM (bis-chloroethylnitrosourea 
300 mg/m2 on day 1, etoposide 200 mg/m2 day 2–5, cyta-
rabine 2 × 200 mg/m2 day 2–5, and melphalan 140 mg/
m2 day 6) and autologous stem cell transplantation. Dur-
ing hospitalization no new skin lesions appeared.
Two months later more skin lesions appeared on the 
lower legs. PET/CT at that moment showed a fibrotic 
lesion in the anterior mediastinum with volume decrease 
and complete resolution of metabolic activity. The patient 
was consolidated with 40  Gy radiotherapy. During this 
treatment additional lesions appeared on the lower legs, 
his general condition was cumbersome. A new biopsy 
confirmed the previous diagnosis of Kaposi’s sarcoma. 
CD4+ count at that time, 3  months after the last HCT 
was at 82/mm3. Later, the spreading of KS stopped and 
on day 182 after HCT CD4+ count rose to 156/mm3.
Nine months after transplantation, counting 227 
CD4+/mm3 in peripheral blood, skin lesions gradually 
disappeared (Fig. 4). A new CT scan confirmed complete 
response status of the lymphoma.
Discussion
In this case study we report a patient with dermal Kapo-
si’s sarcomas associated with HHV-8 appearing shortly 
after autologous stem cell transplantation. Spread was 
limited to the skin; initially the left forearm and lower 
legs, later some abdominal skin lesions appeared. HHV-8 
serology prior to transplantation was not known and not 
a routine examination in our center. With a negative his-
tory in male sexual contact, we consider our patient from 
Moroccan origin to be an endemic carrier.
Fig. 1 Kaposi sarcoma on the right leg
Fig. 2 Endothelial swelling [Skin biopsy, HES (hematoxylin, eosin, 
saffran) routine staining, 200×]
Fig. 3 HHV-8 positivity (Skin biopsy, immune histochemical staining 
HHV-8, 200×)
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Several lines of intensive chemotherapy followed by 
autologous HCT is considered an aggressive form of 
immune suppression, without immune suppressive 
therapy in relation to transplant. The patient‘s immune 
deficient state was confirmed by a low CD4+ count of 
82/mm3 105 days after the last HCT. On day 182 CD4+ 
count rose to 156/mm3 and to 227/mm3 on day 277 
after HCT, coinciding with a remarkable decrease in 
skin lesions. This observation supports that KS in this 
case was related to a low CD4+ count and not a case of 
classic KS.
In our case there was only limited disease of the skin 
without aesthetic concern. We focused on the initial 
disease for further treatment, as this was considered an 
intense treatment option for KS as well. However intense 
chemotherapy using full dose BEAM did not amelio-
rate his original lesions. When new KS were formed, we 
decided to watch and wait for immune recovery. It was 
not until CD4+ count rose to 227/mm3 that the lesions 
clearly faded.
Conclusions
This is the third case of appearance of KS and the first 
describing resolution of Kaposi’s sarcoma with CD4+ 
cell recovery after autologous HCT. Kaposi’s sarcoma 
remains a rare tumor that should be thought of in any 
patient whose immunity is down. If immune recovery 
is expected and disease is limited to the skin, a watchful 
waiting strategy can be more rewarding than intensive 
chemotherapy.
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